2701 Kent Avenue
At Inotiv, we believe our clients should Expect More: more attention, more insight, and a superlative experience when choosing a laboratory partner. We also believe that if YOU Expect More out of your career and have the talent and desire for: more rewarding work, more chances to expand your knowledge, and more opportunities to make a difference in people's lives, that you should apply today. Come be part of a world class CRO that provides services spanning the entire drug discovery and preclinical continuum. Come make a difference with us.
Stock Symbol: NOTV
Stock Exchange: Nasdaq
7 articles with Inotiv
Inotiv, Inc. announced financial results for the three months and six months ended March 31, 2022.
Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced financial results for the three months ended December 31, 2021.
Inotiv, Inc. Announces Closing of $125 Million Convertible Senior Notes Offering and Full Exercise of Option to Purchase Additional $15 Million of Notes
The gross proceeds to the Company were approximately $134.5 million after deducting the initial purchaser’s discounts and commissions and estimated offering expenses.
Inotiv estimates that the net proceeds from the offering will be approximately $120.5 million (or approximately $135.1 million if the initial purchaser fully exercises its option to purchase additional notes), after deducting the initial purchaser’s discounts and commissions and estimated offering expenses.
Inotiv intends to use the net proceeds from the offering of notes, together with borrowings under a new senior secured term loan facility, to fund the cash purchase price of Inotiv’s previously announced acquisition of Envigo RMS Holding Corp. (the “Envigo acquisition”), if it is consummated, and to pay related fees and expenses.
BioVaxys Enters Agreement With Inotiv To Conduct Preclinical Toxicity Studies For Its Covid-T™ Immunodiagnostic Program
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ( "BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it has entered into an agreement with Bioanalytical Systems, Inc. d/b/a Inotiv ("Inotiv"), a global Contract Research Organization ("CRO")
10/23/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.